GenapSys Court Approves Genapsys Sale to Sequencing Health According to the asset purchase agreement, Sequencing Health would offer up to $10 million in cash and assume Genapsys debt of approximately $32 million. Genapsys Founders Lose Bid to Dismiss Bankruptcy Case Genapsys has also obtained a minimum bid for its assets worth approximately $42 million, including $10 million in cash and the assumption of debt. Genapsys Files for Chapter 11 Bankruptcy Protection The Redwood City, California-based sequencing firm laid off more than 70 employees on July 8 after furloughing nearly all of its employees in late June. Sequencing Firm Genapsys, Mired in Lawsuits, Explores Bankruptcy Premium The lawsuits are not the only recent disruption for Genapsys, which laid off approximately 40 employees earlier this year after a $70 million financing in 2021. ABRF Study Benchmarks NGS Platforms on Human, Microbial Samples, Provides Peek at Genapsys Data Premium Illumina's NovaSeq, Oxford Nanopore's Flongle, and Genapsys were among the winners based on the results of the multiyear, multi-center NGS study. Aug 6, 2021 People in the News: New Appointments at Guardant Health, Foundation Medicine, PGDx, GenapSys, More Jul 9, 2021 People in the News: New Appointments at Thermo Fisher, Veracyte, GenapSys, More Jun 25, 2021 People in the News: New Appointments at 23andMe, GenapSys, Akoya Biosciences, More Feb 5, 2021 People in the News: New Appointments at SciLifeLab, Stilla Technologies, Genapsys, Rheonix, More Jan 26, 2021 Bioron to Distribute GenapSys Sequencing Technology in Germany Feb 24, 2020 GenapSys to Offer Twist Bioscience Library Prep, Target Enrichment Products Feb 6, 2020 GenapSys Raises up to $75M in Debt Funding, Signs on More Than 25 Distributors Jan 15, 2020 JP Morgan Healthcare Day 2: 10x Genomics, GenapSys, Caris, Adaptive Bio, Danaher, Agilent, Luminex Nov 26, 2019 GenapSys Targeting Smaller Labs With New Low-Cost Sequencer Premium Nov 20, 2019 GenapSys Raises $90M in Series C Round, Launches Sequencer in US May 24, 2019 Genapsys Publishes Sequencing Data but Questions Linger About Technology Premium Feb 28, 2019 At AGBT, Genapsys Discusses Early-Access Customer Data for New Sequencer Premium Jan 11, 2019 JP Morgan Healthcare, Day 4: Meridian Bioscience, Genapsys, Biocartis, Veracyte Jul 1, 2015 Sigma-Aldrich Enters Co-Marketing Agreement with GenapSys for Genius Sequencer Feb 18, 2014 At AGBT, GenapSys Entices Audience with Lunchbox-Sized Electronic Sequencer; Leaves Open Questions Premium Nov 14, 2013 GenapSys Raises $37M to Commercialize NGS Platform Mar 26, 2013 GenapSys Raises $8.5M of Targeted $13.6M Jan 25, 2013 Syapse Secures $3M in VC Funds to Expand Product Line for Web-based Clinical Omics Analysis Premium Nov 16, 2012 People In The News: Nov 16, 2012 Nov 13, 2012 GenapSys Continues Development of Nanoelectronic Sequencer with $4M in NHGRI Grants Premium Load More Breaking News Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More New Products Posted to GenomeWeb: Qiagen, IDT, Revvity, Mission Bio, NRichDx, More FDA Releases Proposed Rule for Oversight of Laboratory-Developed Tests CStone Pharmaceuticals, Genetron Companion Diagnostic Receives NMPA Approval The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.